牧原股份(002714.SZ):2023年全年屠宰生豬在1300萬頭以上 同比增長80%左右
格隆匯1月11日丨牧原股份(002714.SZ)披露投資者關係活動記錄表顯示,公司屠宰肉食板塊2023年在渠道的開拓與客户的發掘上取得一定成效,全年屠宰生豬在1,300萬頭以上,同比增長80%左右,但距離理想產能利用率仍有一定差距。由於東北廠區投產時間短,產能利用率較低,頭均固定成本較高,當前屠宰肉食業務仍處於虧損狀態,但整體頭均虧損水平已較2022年明顯下降。2024年,公司屠宰肉食板塊會加強銷售能力建設,優化產品結構與客户結構,同時加強內部生產、運營、銷售等板塊的協同,以提升整體盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.